News headlines about Portola Pharmaceuticals (NASDAQ:PTLA) have been trending somewhat positive on Friday, AlphaOne reports. The research firm, a subsidiary of Accern, rates the sentiment of press coverage by monitoring more than 20 million news and blog sources in real time. AlphaOne ranks coverage of public companies on a scale of negative one to one, with scores closest to one being the most favorable. Portola Pharmaceuticals earned a daily sentiment score of 0.19 on AlphaOne’s scale. AlphaOne also assigned press coverage about the biopharmaceutical company an impact score of 74 out of 100, meaning that recent press coverage is likely to have an impact on the company’s share price in the immediate future.
Here are some of the media headlines that may have impacted AlphaOne’s analysis:
- Portola Pharmaceuticals, Inc. (PTLA) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
- Portola Pharma (PTLA) Presents Interim Phase 2a Data for Cerdulatinib at ICML (streetinsider.com)
- Portola Pharmaceuticals : Presents Interim Phase 2a Safety and Efficacy Data for Cerdulatinib at the International Congress of Malignant Lymphoma (4-traders.com)
- Portola Pharma (PTLA) Presents Interim Phase 2a Data for … – StreetInsider.com (streetinsider.com)
- Portola Pharmaceuticals Inc (PTLA) – Pharmaceuticals & Healthcare – Deals and Alliances Profile-Market Research Report Store (mynewsdesk.com)
A number of analysts have recently issued reports on the company. Citigroup Inc. set a $51.00 price objective on Portola Pharmaceuticals and gave the company a “buy” rating in a research report on Wednesday, April 19th. ValuEngine upgraded Portola Pharmaceuticals from a “sell” rating to a “hold” rating in a research report on Friday, June 2nd. Oppenheimer Holdings, Inc. restated a “buy” rating on shares of Portola Pharmaceuticals in a research report on Wednesday, March 22nd. Vetr cut Portola Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $45.18 price objective on the stock. in a research report on Monday, March 20th. Finally, CIBC upgraded Portola Pharmaceuticals from a “market perform” rating to an “outperform” rating in a research report on Friday, February 24th. Three investment analysts have rated the stock with a hold rating and seven have given a buy rating to the stock. The company presently has an average rating of “Buy” and an average target price of $39.90.
Portola Pharmaceuticals (PTLA) traded down 1.13% during mid-day trading on Friday, hitting $35.06. The stock had a trading volume of 1,402,632 shares. The stock’s 50 day moving average price is $38.70 and its 200 day moving average price is $32.19. Portola Pharmaceuticals has a one year low of $15.68 and a one year high of $42.74. The firm’s market capitalization is $2.00 billion.
Portola Pharmaceuticals (NASDAQ:PTLA) last released its quarterly earnings results on Monday, May 8th. The biopharmaceutical company reported ($0.74) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($1.20) by $0.46. Portola Pharmaceuticals had a negative return on equity of 106.68% and a negative net margin of 759.21%. The business had revenue of $5.12 million during the quarter, compared to analysts’ expectations of $4.21 million. During the same period last year, the firm posted ($1.15) EPS. The firm’s revenue for the quarter was down 37.9% compared to the same quarter last year. Analysts forecast that Portola Pharmaceuticals will post ($4.66) EPS for the current year.
In other Portola Pharmaceuticals news, EVP Tao Fu sold 1,097 shares of the firm’s stock in a transaction on Monday, April 10th. The stock was sold at an average price of $36.97, for a total transaction of $40,556.09. The transaction was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, major shareholder (Mauritius) Pte Ltd Maxwell sold 1,700,000 shares of the firm’s stock in a transaction on Thursday, June 1st. The stock was sold at an average price of $34.40, for a total value of $58,480,000.00. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 1,707,847 shares of company stock worth $58,763,961. Corporate insiders own 4.90% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Portola Pharmaceuticals (PTLA) Given Coverage Optimism Score of 0.19” was published by WKRB News and is the property of of WKRB News. If you are reading this piece on another domain, it was copied illegally and republished in violation of US and international trademark and copyright legislation. The legal version of this piece can be read at https://www.wkrb13.com/markets/2229065/portola-pharmaceuticals-ptla-given-coverage-optimism-score-of-0-19.html.
Portola Pharmaceuticals Company Profile
Portola Pharmaceuticals, Inc is a biopharmaceutical company. The Company is focused on the development and commercialization of therapeutics in the areas of thrombosis, other hematologic disorders and inflammation for patients having limited or no approved treatment options. The Company’s two lead programs, Betrixaban and Andexanet alfa, address unmet medical needs in the area of thrombosis, or blood clots.
This story was originally published by WKRB News (https://www.wkrb13.com) and is the sole property of WKRB News. If you are reading this article on another website, that means this article was illegally copied and re-published to this website in violation of U.S. and International copyright law. You can view the original version of this story at https://www.wkrb13.com/markets/2229065/portola-pharmaceuticals-ptla-given-coverage-optimism-score-of-0-19.html
Receive News & Ratings for Portola Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Portola Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.